Literature DB >> 11751896

Domain structure of chondroitin sulfate E octasaccharides binding to type V collagen.

Keiichi Takagaki1, Hidekazu Munakata, Ikuko Kakizaki, Mito Iwafune, Taito Itabashi, Masahiko Endo.   

Abstract

We demonstrated previously that chondroitin sulfate E (ChS-E) binds to type V collagen (Munakata, H., Takagaki, K., Majima, M., and Endo, M. (1999) Glycobiology 9, 1023--1027). In this study, we investigated the structure and binding of ChS-E oligosaccharides. Eleven oligosaccharides were isolated from ChS-E by gel filtration chromatography and anion-exchange high performance liquid chromatography after hydrolysis with testicular hyaluronidase. Separately, seven oligosaccharides were custom synthesized using the transglycosylation reaction of testicular hyaluronidase. Structural analysis was performed by enzymatic digestions in conjunction with high performance liquid chromatography and mass spectrometry. This library of 18 oligosaccharides was used as a source of model molecules to clarify the structural requirements for binding to type V collagen. Binding was analyzed by a biosensor based on surface plasmon resonance. The results indicated that to bind to type V collagen the oligosaccharides must have the following carbohydrate structures: 1) octasaccharide or larger in size; 2) a continuous sequence of three GlcAbeta1--3GalNAc(4S,6S) units; 3) a GlcAbeta1--3GalNAc(4S,6S) unit, GlcAbeta1--3GalNAc(4S) unit or GlcAbeta1--3GalNAc(6S) unit at the reducing terminal; 4) a GlcAbeta1--3GalNAc(4S,6S) unit at the nonreducing terminal. It is likely that these characteristic oligosaccharide sequences play key roles in cell adhesion and extracellular matrix assembly.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751896     DOI: 10.1074/jbc.M106479200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  New endoscopic approach of anti-fibrotic therapy for inflammatory bowel disease.

Authors:  Kenji Suzuki; Hiroyuki Yoneyama
Journal:  Ann Transl Med       Date:  2017-04

2.  Disaccharide analysis of glycosaminoglycans using hydrophilic interaction chromatography and mass spectrometry.

Authors:  Vanessa Leah Gill; Udayanath Aich; Srinivasa Rao; Chris Pohl; Joseph Zaia
Journal:  Anal Chem       Date:  2013-01-03       Impact factor: 6.986

3.  Carbohydrate post-glycosylational modifications.

Authors:  Hai Yu; Xi Chen
Journal:  Org Biomol Chem       Date:  2007-02-06       Impact factor: 3.876

Review 4.  On-line separations combined with MS for analysis of glycosaminoglycans.

Authors:  Joseph Zaia
Journal:  Mass Spectrom Rev       Date:  2009 Mar-Apr       Impact factor: 10.946

5.  A chip-based amide-HILIC LC/MS platform for glycosaminoglycan glycomics profiling.

Authors:  Gregory O Staples; Michael J Bowman; Catherine E Costello; Alicia M Hitchcock; James M Lau; Nancy Leymarie; Christine Miller; Hicham Naimy; Xiaofeng Shi; Joseph Zaia
Journal:  Proteomics       Date:  2009-02       Impact factor: 3.984

6.  Surface plasmon resonance study of protein-carbohydrate interactions using biotinylated sialosides.

Authors:  Matthew J Linman; Joseph D Taylor; Hai Yu; Xi Chen; Quan Cheng
Journal:  Anal Chem       Date:  2008-05-08       Impact factor: 6.986

Review 7.  Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease.

Authors:  Alba B Souza-Fernandes; Paolo Pelosi; Patricia R M Rocco
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

8.  Degree of Suppression of Mouse Myoblast Cell Line C₂C12 Differentiation Varies According to Chondroitin Sulfate Subtype.

Authors:  Katsuhiko Warita; Nana Oshima; Naoko Takeda-Okuda; Jun-Ichi Tamura; Yoshinao Z Hosaka
Journal:  Mar Drugs       Date:  2016-10-21       Impact factor: 5.118

Review 9.  Synthesis of neoproteoglycans using the transglycosylation reaction as a reverse reaction of endo-glycosidases.

Authors:  Masahiko Endo; Ikuko Kakizaki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.